It seems that at 15mg you get almost 100% of the glucagon activity from the retatrutide, so I wanted to try. Definitely stronger on the appetite suppression but sides effect are inexistant for me. I feel great.
I’m starting to be very lean 7-8% BF maybe so I might become less sensitive to the effect.
2 Likes
I do agree retatrutide is a potent blood pressure reducing drug and in my case, I’m just on 2mg and not losing weight since I don’t have much to lose so it’s a direct drug effect.
Is there a reason you like Reta over Tirzepatide? I’ve done both, and prefer Tirzepatide more. Both increase my RHR, but Reta is noticeably higher. Tirzepatide helps with appetite suppression and food noise beta than Reta for me. There are other compounds that can combat that though.
On the flip side, Gastric emptying is a little bit less of an issue with Reta. And weight certainly drops off faster.
Just to share an n=1 on glp1s and heart rate.
This morning I did a deep dive with Fable (Claude).
He fetched my Oura history from when they created the website in 2021. My heart rate went up 3 bpm when I started semaglutide. It quickly stabilized.
I found it interesting to learn it never went any higher after switching to TZ or RT.
I’ve never been on a high dose on any of the 3, but I was pleasantly surprised to learn RT had zero additional effect.
4 Likes
Retatrutide vs Semiglutide & Tirzepatide: Should YOU Actually Take It? (via Quinn Stillson MD)
I. Executive Summary
The analyzed discourse evaluates the therapeutic profile of retatrutide—a novel, synthetic 39-amino-acid triple agonist peptide developed by Eli Lilly—against established incretin therapies, specifically semaglutide (a selective GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist). Emerging data from phase III trials demonstrate that retatrutide achieves unprecedented weight reduction, averaging 28.7% total body weight loss at 68 weeks with the highest dose. Mechanistically built upon a gastric inhibitory polypeptide (GIP) structural backbone, retatrutide simultaneously co-activates three distinct receptors at asymmetric potencies: it acts as a hyper-potent agonist at the GIP receptor (8.9 times endogenous potency) while functioning as a lower-potency biased agonist at the glucagon receptor (30% potency) and the GLP-1 receptor (40% potency). Its biased GLP-1 receptor agonism selectively activates the intracellular G-protein/cAMP cascade while minimizing beta-arrestin recruitment, theoretically mitigating receptor desensitization.
Despite its exceptional efficacy in inducing mass reduction and profound clearing of hepatic steatosis (an 82% reduction in liver fat within 24 weeks), a critical translational and safety gap emerges when evaluating retatrutide for broader healthspan and longevity optimization in non-obese cohorts. The continuous pharmacological activation of the glucagon receptor introduces complex metabolic tradeoffs. While it drives hepatic fatty acid oxidation, decreases lipid synthesis, and downregulates the PCSK9 enzyme to achieve dramatic reductions in circulating LDL-C and triglycerides, it simultaneously accelerates hepatic amino acid catabolism. This catabolic pathway raises concerns regarding potential inhibition of muscle protein synthesis and acceleration of lean mass loss, which currently mirrors semaglutide’s profile (~36% of total weight lost derived from lean mass in diabetic cohorts).
Furthermore, retatrutide exhibits a unique and potentially concerning cardiovascular and immunological fingerprint: it does not significantly elevate cardioprotective HDL-C, suppresses diastolic blood pressure reduction, induces a transient but substantial increase in resting heart rate (+6.7 beats per minute), and significantly elevates the risk of cardiac arrhythmias (11% to 14% incidence) and dysesthesia (20.9% incidence at peak doses). From a direct geroscience perspective, independent of weight loss, selective GLP-1 activation mirrors rapamycin-like longevity signatures by downregulating mTOR and upregulating autophagy. Conversely, retatrutide’s hyper-potent GIP activation suppresses sirtuin 1 (SIRT1), potentially undermining key longevity pathways in leaner individuals. Because its cardiovascular outcomes trial will not conclude until 2029–2030, and its published literature base is 30 to 60 times smaller than tirzepatide and semaglutide respectively, retatrutide remains an experimental compound whose organ-level risks outweigh its benefits in non-obese or cardiomechanically vulnerable populations.
II. Insight Bullets
- Triple Receptor Agonism Architecture: Retatrutide is a synthetic 39-amino-acid peptide engineered to simultaneously stimulate GLP-1, GIP, and glucagon receptor signaling cascades.
- Structural GIP Dominance: Despite being grouped into the general GLP-1 class, retatrutide is structurally derived from an endogenous GIP backbone, making it chemically distinct from native GLP-1 molecules.
- Asymmetric Activation Potencies: Retatrutide exhibits highly asymmetrical receptor kinetics, firing GIP at 8.9 times native potency, while hitting GLP-1 at 40% and glucagon at 30% native potency.
- Biased Agonism Mechanics: At the GLP-1 receptor, retatrutide acts as a biased agonist, preferentially activating the therapeutic G-protein/cAMP pathway while minimizing the desensitizing beta-arrestin pathway.
- Enzymatic Stabilization and Extension: Retatrutide combines a position-2 amino acid substitution to block dipeptidyl peptidase-4 (DPP4) degradation with a position-17 fatty acid chain to facilitate reversible albumin binding, extending its half-life to 6 days.
- Continuous vs. Pulsatile Signaling: Unlike endogenous incretins that discharge in brief physiological pulses, retatrutide imposes chronic, unremitting receptor activation across all three target networks.
- Biphasic Central Appetite Regulation: GLP-1 signaling drives weight loss by concurrently blunting homeostatic metabolic hunger in the hypothalamus and suppressing hedonic reward signaling in the mesolimbic pathway.
- Independent End-Organ Protection: Selective GLP-1 receptor activation yields potent cardiovascular and renal protection via receptors on endothelial, immune, and renal cells, independent of aggregate weight loss.
- GIP-Driven Nausea Suppression: GIP receptor activation within brainstem neurons directly counteracts the emetic, nausea-inducing signals triggered by GLP-1 agonism, optimizing gastrointestinal tolerability.
- Mixed Extra-Metabolic GIP Signals: GIP receptors are absent in the kidney and demonstrate highly conflicting, context-dependent inflammatory effects in the cardiovascular system, contrasting with uniformly beneficial GLP-1 signaling.
- GIP-Mediated Alveolar Preservation: The clearest non-metabolic benefit of sustained GIP activation is the robust inhibition of osteoclast-mediated bone resorption, preserving mineral density.
- Hepatic Glucagon Counterbalance: Co-activating the glucagon receptor alongside GLP-1 and GIP allows the downstream insulinogenic responses to completely neutralize glucagon’s baseline glycogenolytic, blood-sugar-elevating effects.
- Unverified Energy Expenditure Claims: The widely repeated claim that glucagon co-activation elevates resting metabolic rate lacks robust human backing; clinical trials show weight loss is driven almost entirely by voluntary caloric restriction rather than increased thermogenesis.
- Unprecedented Weight Loss Magnitude: Phase III data demonstrate that retatrutide drives a peerless 28.7% mean reduction in total body weight at 68 weeks at maximum dosing.
- Targeted Hepatic Delipidation: Glucagon receptor stimulation in hepatocytes accelerates fatty acid beta-oxidation and halts lipid synthesis, inducing a massive 82% reduction in liver fat within 24 weeks.
- PCSK9 Degradation Mechanism: Retatrutide achieves a dramatic 21.7% reduction in circulating LDL-C by stimulating liver-level glucagon receptors to degrade the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme.
- HDL-C Clearing Side Effect: The same hepatic glucagon pathways that clear atherogenic lipids also inadvertently degrade beneficial high-density lipoprotein particles, preventing the HDL-C increases typically seen with tirzepatide.
- The Lean Mass Catabolism Risk: Chronic glucagon receptor activation forces the upregulation of hepatic amino acid catabolism, threatening skeletal muscle preservation by shifting amino acids toward energy substrate production.
- Relative Sarcopenic Proportions: Dual-energy X-ray absorptiometry (DEXA) sub-studies indicate that lean mass comprises 36% of the total weight lost under retatrutide, roughly matching semaglutide (~35%) but tracking higher than tirzepatide (~25%).
- Sympathetic Cardiovascular Fingerprint: Retatrutide increases resting pulse rate by up to 6.7 beats per minute and limits diastolic blood pressure reduction due to glucagon-mediated sympathetic nervous system stimulation.
- Pro-Arrhythmic Signal Emergence: Phase II data show that retatrutide induces a 11% to 14% incidence rate of cardiac arrhythmias, a signal significantly elevated relative to mono- or dual-incretin therapies.
- The Postmarket Surveillance Deficit: While semaglutide possesses over 40,000 patient-years of published clinical trial data and millions of real-world user tracking years, retatrutide’s published database is restricted to fewer than 700 patients.
- High-Dose Attrition Rates: Retatrutide’s maximum-dosage cohorts display an 18.2% treatment discontinuation rate, more than double the attrition seen in comparable semaglutide or tirzepatide arms, indicating a higher severity of adverse events.
- Neurological Dysesthesia Signal: Phase III data reveal a novel neurological side effect: 20.9% of patients on high-dose retatrutide develop cutaneous dysesthesia (burning or tingling skin sensations) compared to 0.7% on placebo.
- SIRT1 Longevity Pathway Suppression: Preclinical data show that hyper-potent GIP signaling suppresses sirtuin 1 (SIRT1)—a critical cellular survival pathway activated by caloric restriction—presenting a distinct molecular hazard for lean longevity seekers.
IV. Actionable Protocol
High Confidence Tier (Level A/B Evidence)
- Severe Class III Obesity Elimination: Deploy retatrutide preferentially in individuals presenting with an initial BMI greater than 35, where a ~28% body mass reduction drastically shifts all-cause mortality vectors and safely outweighs any unquantified organ-level risks.
- Advanced Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) Reversal: Utilize retatrutide as a targeted therapeutic tool for rapid hepatic delipidation in cases of severe metabolic fatty liver disease, leveraging its glucagon-mediated mechanism to achieve a rapid ~82% reduction in intrahepatic triglyceride storage.
Experimental Tier (Level C/D Evidence)
- Hyper-Triglyceridemic and Low-LDL Refractory Management: Consider retatrutide for patients with severe metabolic syndrome displaying refractory hypertriglyceridemia and elevated LDL-C who fail to reach lipid targets on maximum dual-incretin therapy, exploiting its native PCSK9-degradation pathway.
- Skeletal Muscle Sarcopenia Mitigation: If utilizing retatrutide, mandatorily execute serial body composition monitoring (via DEXA, Bioelectrical Impedance Analysis, or equivalent multi-sensor metrics) to actively audit the lean mass-to-fat loss ratio, aggressively adjusting dietary protein intake and mechanical resistance training loads to counteract accelerated amino acid catabolism.
2 Likes
Very good summary overall. Notes :
- energy expenditure form glucagon is pretty much a myth that people keep repeating, like the author said. It’s notable in mice studies (surprise, surprise ) but a rounding error in humans
- I’m more and more skeptical of muscle loss (not lean mass loss ) measured by dexa. Sadly, the companies conducting these studies don’t do themselves any favors by using dexa most of the time. But the studies that bothered to use mri show that muscle loss is way less than 30%. Recent study that showed that muscle loss for a GLP1/GCGR agonist is only 10%: Survodutide Once Weekly for the Treatment of Adults with Obesity (body composition results). We have similar mri data from semaglutide where muscle mass was around 15%. Funnily enough, liver mass reduction can account for 20% of lean mass loss, which surprised me.
- author mentioned retatrutide not raising hdl, as if raising hdl has proven to have any beneficial effect on cvd. Not relevant, in my view.
- I don’t really get the reasoning behind the obese vs non obese case for not using retatrutide. That’s probably because the author thinks most of the metabolic improvements are only weight dependent. My own labs show that’s not the case, so for my n=1 case, I think the author is wrong.
- worries about overactivation of glucagon receptor doesn’t make sense to me. In those studies, the activation is not only chronic, but it doesn’t come with GLP1 activation, which secretes insulin, counterbalancing glucagon. We have extensive human data showing that glucagon by itself is a no go (including trials) , so this is not some new issue discovered in mice studies cited by the author.
Fun fact about GIP : you get metabolic benefits from it (pretty much the same ones ) whether you agonise it, or suppress it. No one is sure why. Bone density concerns when it comes to suppression are so far mechanistically sound, but not proven in humans.
3 Likes
Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
“Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial’s primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( − 4.9 years/year, p = 0.004), PCGrimAge ( − 3.1, p = 0.007), GrimAge V2 ( − 2.3, p = 0.009), OMICmAge ( − 2.2, p = 0.009), RetroAge ( − 2.2, p = 0.030), and DunedinPACE ( − 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.”
1 Like
metformin will work in this context as well
Please share this contacts. What shop is it? Have you try this?
And anyone - can you give me a contacts of reliable cheap chinese shop, maybe from made-in-china.com? or any other site.
If looking for Chinese grey peptides, read this Retatrutide - Possibly better than semaglutide b/c lower nausea/side effect profile, but higher heart rate - #248 by qBx123Yk
Thanks. But its a bad site. No list of vendors, unnecessary accent on cryptocurrencies. All the normal sellers use bank transfer, and have representatives on major sites like alibaba, made-in-china ans so on. No need to play spygames “wwooooh, we are on a DARK NET!”
Just need a contact as in the thread for indian pharmacies for Rapamycin.
1 Like
Understood. You should be able to find sites saying they sell peptides from a relatively simple internet search then.
1 Like
I agree on this. But I disagree that cryptocurrencies are necessary. A lot of these vendors get blacklisted by banks and are forced to use cryptocurrency.
These type of grey market peptide vendors often come and go a lot more than the Indian pharmacies so it’s harder to keep track of what is good and what is not. This has caused people to say “just do your own research” to find the best vendor but I think we should aim to have a list of viable vendors in the same way we have Indian pharmacies here.
Not everyone has time to deep dive on researching Chinese vendors and it is very tiresome, but people who do look into it often vet many and can list ones they’ve found to be reliable at the time.
1 Like
Thanks. https://glp1forum.com for example. I found it very helpful with a real (i hope, they look like) reviews on sellers and with many tests of batches.
I continue to benefit from 1.0 mg. It is the best item in my stack, but not the only good one.
3 Likes
Actually I have found that my initial hypothesis that Telmisartan acts synergistically to reta is probably accurate…
So, I initially found it tough to go above around 4mg-5 mg without strong appetite suppression (too strong, I want to enjoy food and stop the weight loss where it is)… during this time period I was concerned about the fact that I was hovering near hypotension so I tried to quit telmisartan for a few weeks… it was during that time period where the appetite suppression was gone and I moved up in mg… Once I got my blood work that shown for me positive results taking both reta/telmisartan and hovering near hypotension (without symptoms) I made the guess that near hypotension doesn’t have to be bad and I started taking both again… during that time have had to down regulate reta again due to bothersome appetite suppression
2 Likes
I also dropped telmisartan due to Reta but am not planning to re-introduce it for now
2 Likes
1. Executive Summary
This is an opinion-framed “mind changed” video from a creator (self-identified as a neuroscience PhD, referred to as “Nick” in the Q&A) who describes shifting from GLP-1 skepticism toward viewing these drugs as broadly beneficial well beyond weight loss. He frames this explicitly as personal opinion, not medical advice, and states he has no pharma financial ties.
The video moves through six parts: societal framing (adoption trends, obesity rate shifts, food industry response), common safety concerns (muscle loss, bone health, eye health, thyroid risk), the three “generations” of GLP-1-class drugs ending with the triple agonist retatrutide, weight-independent effects (Alzheimer’s pathology, osteoarthritis/cartilage), combination therapies for simultaneous fat loss and muscle gain (myostatin/activin-A inhibitors, ATX304), and an audience Q&A covering oral GLP-1s, rebound weight gain, addiction/craving effects, and gastroparesis.
He closes by stating his current view is that benefits outweigh risks for most people, “provided someone doesn’t lose too much weight” — explicitly flagged as opinion, not a medical claim.
2. Actionable Insights
Resistance training + protein target during GLP-1 use
- What: 3+ resistance sessions/week, ~0.7–1g protein per lb of lean mass while losing weight
- Risk: Low — standard sports-nutrition guidance, not GLP-1-specific
- Evidence tier: Stated by the speaker as “a reasonable rule of thumb,” not tied to a specific trial in the transcript — treat as practitioner heuristic
Slow dose titration + avoiding overeating (gastroparesis mitigation)
- What: Start low, escalate slowly, avoid large meals especially at high doses
- Risk: Low — sensible general guidance
- Evidence tier: General clinical reasoning stated in transcript, not tied to a specific study
Oral GLP-1 (orforglipron — transcript garbles the name)
- What: Non-peptide oral GLP-1; transcript states ~11.2% body weight reduction over 72 weeks
- Risk: Low-moderate, described as similar profile to existing GLP-1s
- Evidence tier: Human RCT — verified below in Claims Requiring Scrutiny; the exact figure needs a small correction
ATX304 (AMPK activator)
- What: Framed as pulling fuel into muscle while increasing fat oxidation; speaker mentions personal use (lowered his fasting glucose by 6 mg/dL) and recommending it to two family members
- Risk: Speculative-to-high — unapproved research compound, no human data for this specific compound in the transcript. The personal/family anecdotes are testimonial, not evidence, and the speaker explicitly says “not medical advice”
- Evidence tier: Animal only. Transcript specifies a 32-day study, 21% body weight reduction, “100% from fat”; species not named in transcript — this is a gap, not filled in here. The “no lean mass loss when combined with GLP-1s” claim is also animal-only per transcript, species again unspecified.
Myostatin/activin-A inhibitors + GLP-1
- What: Blocking muscle-growth “brakes” alongside GLP-1s for simultaneous fat loss/muscle gain
- Risk: Speculative — early-stage, not accessible outside trials
- Evidence tier: Animal — monkey (specified in transcript) for the 50% fat mass loss / 6% lean mass gain result. The human figure cited (3kg lean gained, 4kg fat lost over 8 weeks) needs correction — see Claims Requiring Scrutiny below.
Testosterone replacement for diagnosed hypogonadism (context within the Nicholas N case study)
- What: 200mg/week testosterone, replacement-dose (not supraphysiologic), prescribed for medically diagnosed low testosterone, alongside retatrutide, diet, and resistance training
- Risk: Low when medically diagnosed and monitored — standard-of-care hormone replacement, not off-label enhancement — but only applies to someone with an actual diagnosis, not a general recommendation
- Evidence tier: Single case study (n=1), not a controlled trial
3. Safety Concerns
- Thyroid: Warning specifically for personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Concern originates from rodent studies per the transcript, not established human carcinogenicity.
- Eyes (NAION): Transcript cites “a 2026 systematic review” finding no significant association, with an absolute risk estimate of “something like half a percent in patients with diabetes over 5 years” — unverified, see below. Caution flagged for pre-existing retinal or diabetic eye disease regardless.
- Gastroparesis: True pathologic stomach paralysis is distinguished from the drug’s intended slowed-gastric-emptying mechanism. Severity/prevalence figures beyond “relatively uncommon” aren’t given.
- Cardiac load (retatrutide specifically): Increased resting heart rate and cardiac load from the glucagon-receptor component flagged as an open long-term question by the speaker himself.
- Populations needing more caution per transcript: pre-existing retinal disease, personal/family thyroid cancer history, MEN2.
- Not mentioned in transcript but worth flagging: pregnancy, pancreatitis history, and gallbladder disease are commonly discussed GLP-1 contraindications elsewhere that this video doesn’t address — a notable omission if you’re using this as a source.
4. Signals Worth Watching
Retatrutide’s proposed PCSK9-lowering mechanism
- What/stage: Speaker’s own n=1 self-experiment (1–2mg for 4 weeks), reporting LDL/ApoB drops he attributes partly to glucagon-receptor-mediated PCSK9 reduction
- Vs. existing interventions: Mechanistically distinct from statins (HMG-CoA reductase inhibition) or PCSK9 monoclonal antibodies (evolocumab/alirocumab) — not stated in transcript, added for context
- What’s needed: The transcript notes a confounding second compound taken concurrently (“azetoide”). A controlled trial isolating retatrutide’s independent lipid effect is needed.
FGF-21-mediated muscle-sparing hypothesis for retatrutide
- What/stage: Explicitly the speaker’s own unpublished hypothesis about FGF-21 resistance in obese vs. lean populations
- Comparison: Mechanistically novel relative to behavioral muscle-preservation strategies (resistance training/protein) — an endocrine rather than behavioral lever
- What’s needed: Direct comparison of FGF-21 sensitivity and lean mass outcomes across BMI strata on retatrutide specifically
GLP-1 and Alzheimer’s pathology (BACE1/amyloid, GSK-3β/tau)
- What/stage: Population correlational data plus two proposed direct mechanisms — GLP-1 inhibiting BACE1 and improving brain insulin signaling to reduce GSK-3β-driven tau hyperphosphorylation
- Comparison: Places GLP-1s in a different category from anti-amyloid monoclonal antibodies (lecanemab, donanemab) — not mentioned in transcript, added for context
- What’s needed: RCTs with cognitive/biomarker endpoints in non-diabetic, non-obese populations to separate direct brain effects from metabolic-improvement confounding
Cartilage thickening / osteoarthritis effects
- What/stage: “A 2026 study” (unnamed) reporting GLP-1 association with cartilage thickening in humans
- What’s needed: The specific study, its design, and whether thickening correlates with functional/pain outcomes — none of this is in the transcript, and I did not locate it in this pass
5. Deep Dive
- DEXA lean-mass-vs-liver-mass claim: The underlying DEXA critique is legitimate — DEXA genuinely cannot separate contractile protein from glycogen-bound water, organ mass, or connective tissue. But no study is named, and “preferentially reduce liver mass” is doing significant work: hepatic steatosis reduction on GLP-1s is well-documented, but whether that fully accounts for the 25–40% lean-mass-loss figure cited elsewhere is left unresolved.
- Bone: The osteoblast-stimulating/osteoclast-inhibiting framing is mechanistically plausible, and the rat insulin-resistance study is specified as animal in the transcript. But the downstream signaling from “GLP-1 receptors in bone cells” to osteoblast/osteoclast balance is stated without receptor subtype or pathway detail.
- Generation classification and weight-loss percentages: The three-generation framing is standard for how the field discusses this progression. The figures given (10–15% / ~20% / ~24%, ~28% in women) are broadly in range of published retatrutide data, likely TRIUMPH-1, but the transcript names no trial.
- “Wanting vs. liking” framing: A legitimate, well-established distinction in addiction neuroscience, applied correctly at a conceptual level, though the specific genetic-variant studies referenced aren’t named.
- PCSK9 mechanism plausibility: Glucagon receptor agonism affecting PCSK9 expression is biologically plausible, but presented via a single confounded self-experiment — far short of establishing the mechanism.
6. Claims Requiring Scrutiny
“US obesity rate fallen from ~40% to ~37%… 7.6 million fewer obese adults”
Checked against Gallup’s National Health and Well-Being Index — this is accurate. Obesity peaked at 39.9% in 2022 and fell to 37.0% in 2025, ~7.6 million fewer obese adults, alongside GLP-1 use for weight loss rising from 5.8% (Feb 2024) to 12.4% (2025). Caveat Gallup itself notes: this is self-reported survey data, and the obesity decline is correlational with GLP-1 uptake, not proven causal — other factors aren’t ruled out.
Oral GLP-1 (orforglipron) — “11.2% body weight reduction over 72 weeks”
Checked against the published ATTAIN-1 Phase 3 trial (NEJM) — the actual figure is 12.4% weight reduction (27.3 lbs) at the highest (36mg) dose at 72 weeks. Close to the video’s number but not exact, and the video doesn’t specify dose. Use 12.4% at 36mg if citing this.
Myostatin/activin-A human trial (“3kg lean mass gained, 4kg fat lost over 8 weeks, single treatment”)
This appears to be a garbled recollection of the real BELIEVE trial (bimagrumab + semaglutide, published in Nature Medicine, presented at ADA 2025) — but the actual numbers don’t match. BELIEVE ran 48–72 weeks with repeated dosing, not a single 8-week treatment. In the combination arm, lean mass was reduced by 2.9% (better preserved than semaglutide alone’s 7.4% loss, but not a gain); bimagrumab monotherapy alone showed a 2.5% lean mass increase. The “3kg gained / 4kg lost” figures don’t appear in the sources I found. Treat this as likely misstated — cite the actual BELIEVE data instead if you cover it.
“2026 systematic review found no significant association” (NAION/vision)
Not verified in this pass — I could not locate a specific named 2026 systematic review on GLP-1s and NAION. This doesn’t mean one doesn’t exist, but the claim remains as unsourced as the transcript presents it.
“A 2026 study” on cartilage thickening / osteoarthritis, and “2026 research” on DEXA/liver mass
Not checked in this pass — no compound or trial name in the transcript to search against.
Overall thesis (“maybe everyone should be taking a GLP-1”)
Not a factual claim — explicitly rhetorical framing per the speaker, who hedges by the end.
ATX304 anecdote and Nicholas N case study
Not independently checkable — personal testimonial and single self-reported case, not verifiable trial data.
7. Discussion Prompts
What happens to a food and pharmaceutical economy that reorganizes itself around a drug class whose 20-year cardiovascular and cancer safety data don’t yet exist — and is the individual risk/benefit calculus (“is this good for me”) actually a different question from whether society adapting its infrastructure around these drugs this quickly is a good idea?
The FGF-21 muscle-sparing hypothesis is explicitly the speaker’s own unpublished idea, not literature consensus — if a claim like this spreads faster than its evidentiary basis, what’s the mechanism by which it usually gets corrected or reinforced within the biohacker/longevity information ecosystem, and does that mechanism work fast enough?
8. Citations
No sources named with full detail anywhere in the transcript. Referenced but unnamed: “a 2026 systematic review” (NAION), “2026 research” (DEXA/liver mass), “a 2026 study” (osteoarthritis/cartilage). Named individual: “Nicholas N” (community case study, self-reported, n=1). Named product/newsletter: metabetism.com (“Stay Curious”). Verified externally in this pass: Gallup National Health and Well-Being Index (obesity/GLP-1 usage stats), Lilly’s ATTAIN-1 Phase 3 trial (orforglipron), the BELIEVE trial (bimagrumab + semaglutide, Nature Medicine).
1 Like
The path used by retatrutide to lower LDL is thought to be ANGPTL3/8 pathway. From ESC 365 - Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels
Baseline ANGPTL3/8 levels (mean 26.3 ng/mL, IQR 17.4-33.0 ng/mL) were not different among all study groups. Mean percent changes of ANGPTL3/8 from baseline at week 24 were -1.3%, -12.0%, -48.7% and -51.0% in 0.5 mg, 4 mg, 8 mg and 12 mg retatrutide groups, respectively (Figure). Percent changes of ANGPTL3/8 in 8 mg and 12 mg retatrutide groups were significantly different from placebo group (p < 0.0001). Mean
percent changes of PCSK9 levels from baseline to 24 weeks were not different from placebo for any treatment arm (+6.2%, -3.9%, -3.8% and -9.6% for retatrutide 0.5 mg, 4 mg, 8 mg and 12 mg groups, respectively, and -1.5% for dulaglutide and -6.5% for placebo).
Here’s what AI says about how retatrutide uses this pathway to help lower LDL
This is another way to lower LDL, but not panacea. I didn’t see any additional lowering of LDL in my case by adding retatrutide. In my case, blocking absorption was much, much more effective via Ezetimibe.
2 Likes
I’ve bought it from some obscure supplier. 1st dose was 0,5, second 1,5, now made 3mg. Was on tirza 3-6mg for several months, and sema for 1,5 years.
I do feel nothing. May it be too low dose for not-naive person? Or may it be fake reta from china? Frankly there are not much bad stories about 0% of active peptides in an already recieved parcels. Scam happens, but nobody send nothing at all usually.
So I think its too low dose for me, but a lot of people say its “very powerful” and so on. Should I wait more weeks? Should I go up, maybe to 4-5-6mg? My appetite is normal. Not completely gone as it was on sema for a first 1-3 months. Sometimes I really feel hungry. And for 3 weeks no weight loss. Not gain either.
I’m a bit confused.